Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System
Endospan, a pioneer in endovascular solutions for complex aortic pathologies, today announced that Artivion, Inc. (NYSE: AORT) has closed the transaction to acquire the company. This strategic milestone follows the April 2026 U.S. Food and Drug Administration (FDA) PMA approval of the NEXUS® Aortic Arch System, the first off-the-shelf endovascular solution designed to treat aortic arch disease, including chronic aortic dissections, in patients at high risk for open surgical repair. The purchase price for the acquisition is $175M less offsets for previously provided loans, plus a potential for up to $200M in additional consideration contingent upon U.S. NEXUS commercial performance over the next two years.
For the surgical community, this marks the integration of the NEXUS system into the most comprehensive global portfolio of solutions to treat the aortic arch. By joining Artivion, Endospan’s innovative endovascular technology will be supported by a leading company in cardiac and vascular surgery, facilitating broader access to "best-in-class" solutions for most of the aortic treatment scenarios.
